Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

LOGOGRAM: Validation of Allergy Care Flowcharts in Primary Care: Experience From Occitanie (LOGOGRAM)

2. juni 2026 opdateret af: University Hospital, Montpellier

Validation Des Diagrammes de Flux d'Allergies en Soins Primaires : expérience de la région Occitanie

This study, aimed at validating decision trees developed through collaboration between general practitioners and allergists, seeks to provide French data to optimize care pathways for patients with allergic diseases from the primary care level and to reduce the delays and negative consequences associated with incorrect diagnoses. Most patients with allergic conditions are initially seen in primary care, often during exacerbations. Although allergies, in their many clinical forms, account for approximately 6-8% of primary care consultations, clinicians frequently receive little or no formal training in this field and may not be fully aware of the latest evidence, associated risks, or appropriate referral pathways. These gaps can significantly affect the quality of care and patients' quality of life, while also contributing to higher morbidity and mortality. In this context, the European Academy of Allergy and Clinical Immunology established a multidisciplinary task force to transform existing allergy guidelines into simple, practical, and accessible tools to facilitate diagnosis and management in primary care. The group developed five decision trees covering asthma, anaphylaxis, drug allergy, food allergy, rhinitis, and urticaria to support primary care physicians and other non-specialists in managing patients with symptoms suggestive of allergic or hypersensitivity reactions. The results of this project will be directly applicable to the daily clinical practice of general practitioners in France and could serve as a model for replication in other regions and countries, although adaptations may be required depending on national healthcare systems.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

600

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Frankrig
    • Occitanie
      • Béziers, Occitanie, Frankrig, 34500
      • Cabestany, Occitanie, Frankrig, 66330
      • Montpellier, Occitanie, Frankrig, 34080
      • Narbonne, Occitanie, Frankrig, 11100
      • Nîmes, Occitanie, Frankrig, 30000
      • Perpignan, Occitanie, Frankrig, 66000
      • Roujan, Occitanie, Frankrig, 34320
      • Saint-Georges-dOrques, Occitanie, Frankrig, 34680
        • Département Universitaire de Médecine Générale MSPU CHU Montpellier
        • Kontakt:
      • Saint-Marcel-sur-Aude, Occitanie, Frankrig, 11120
      • Tourbes, Occitanie, Frankrig, 34120

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Patients with suspected asthma, anaphylaxis, drug allergy, food allergy, rhinitis and urticaria.
  • Patients aged 1 year or older at inclusion, registered with a health insurance plan.
  • Patient or legal representative of the minor patient who agrees to participate in the research.

Exclusion Criteria:

  • Adults placed under guardianship or curatorship.
  • Patients already followed by an allergist and/or a specialist doctor for their allergies.
  • Patients who participate in a clinical research study relating to an antiallergic medication, immunosuppressant, immunomodulator in the year preceding their consultation visit with the GP.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Interventional arm
Patients consulting in participating centers after implementation of decision trees designed to support physicians in the diagnosis and management of allergic diseases
Andet: Implementation of an innovative tool based around AI-automated decision trees on an application
The application provides immediate access to the algorithms (decision trees). Investigators can access a dedicated interface and enter participant data, including the suspected diagnosis, symptoms, acute episode or history of allergic disease, and the medical decision made (diagnosis, therapeutic management, or referral to a specialist). Management options based on the five algorithms are then generated to support physicians in the diagnosis and management of allergic diseases.
Ingen indgriben: Non-interventional arm
Patients consulting in participating centers before implementation of clinical decision trees intended to support physicians in the diagnosis and management of allergic diseases.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Rate of referral to allergy specialists following primary care consultations for allergic diseases
Tidsramme: through study completion, an average of 4 years
Comparison of the proportion of patients referred to an allergy specialist by general practitioners after consultations for suspected allergic diseases before and after implementation of the clinical decision trees in participating centers.
through study completion, an average of 4 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ease of use of the clinical decision trees
Tidsramme: through study completion, an average of 4 years
The ease of use of the clinical decision trees will be assessed using an online questionnaire completed by general practitioners at the end of their participation. The questionnaire will evaluate ease of use (score from 1 to 5, from very difficult to very easy), precision of the clinical decision trees (score from 1 to 5, from inaccurate to very precise), confidence felt during their application in clinical practice (score from 1 to 5, from not confident at all to totally confident), average duration of use (minutes), and willingness to continue using the clinical decision trees in routine practice (yes/no).
through study completion, an average of 4 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University Hospital, Montpellier

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

1. september 2030

Studieafslutning (Anslået)

1. september 2030

Datoer for studieregistrering

Først indsendt

27. maj 2026

Først indsendt, der opfyldte QC-kriterier

2. juni 2026

Først opslået (Faktiske)

5. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juni 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • RECHMPL23_0327
  • 2025-A02183-46 (Registry Identifier: ID-RCB)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner